About OM Pharma
OM Pharma is a company based in Meyrin (Switzerland) founded in 1937 was acquired by Optimus Holding in September 2020. OM Pharma operates in a competitive market with competitors including Serum Institute of India, Vaxcyte, Portola Pharma, Vir Biotechnology and Biological E, among others.
- Headquarter Meyrin, Switzerland
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website ompharma.com/home
- Social LinkedIn
- Acquired by Optimus Holding (Sep 2020)
Investors in OM Pharma
OM Pharma has secured backing from 1 investor. Prominent investors backing the company include Optimus Holding.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | Optimus Holding Ltd.tcc.mode | - |
Investor details for OM Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of OM Pharma
2 people are tracked at OM Pharma (2 in team).
| Name | Role | Group |
|---|---|---|
Etienne Jornod | Executive Chairman | Team |
Audrey Lecordier | Personal Assistant To The Executive Chairman | Team |
Complete people profiles for OM Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of OM Pharma
2 dated milestones of OM Pharma across 83 years, from founding to its latest funding, stage changes and deals.
- Founded OM Pharma is founded.
- Exit Acquired by Optimus Holding.
Competitors of OM Pharma
OM Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Serum Institute of India, Vaxcyte, Portola Pharma, Vir Biotechnology and Biological E, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| seruminstitute.com | 1966 | Pune, India | – | 6,617 | Vaccines and immuno-biological drugs for infectious diseases are manufactured. | |
| vaxcyte.com | 2013 | Foster, United States | $347M | 254 | Vaccines for infectious diseases are developed using cell-free protein synthesis. | |
| portola.com | 2003 | San Francisco, United States | $296.09M | 369 | Therapeutics for cardiovascular and autoimmune diseases are developed. | |
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases | |
| biologicale.com | 1953 | Hyderabad, India | – | 6,099 | Vaccines and therapeutics for multiple diseases are developed and marketed. | |
| myokardia.com | 2012 | San Francisco, United States | $98M | 224 | Specialized drugs are developed for genetic heart diseases. | |
| cellinobio.com | 2017 | Cambridge, United States | $125M | 63 | Developer of autologous cell therapies | |
| arrakistx.com | 2015 | Waltham, United States | $113M | 91 | Provider of tools for the analysis of RNA structures | |
| freeline.life | 2015 | Stevenage, United Kingdom | $273.69M | 152 | Gene therapy platform is developed for chronic disease treatments. | |
| stridebio.com | 2015 | Durham, United States | $98.2M | 109 | AAV-based gene therapies for rare diseases are developed. |
Detailed competitors of OM Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of OM Pharma
The website of OM Pharma (ompharma.com) receives about 10.7K visits a month and ranks #2,716,683 among all websites worldwide, #3,677 in Biotechnology and Pharmaceuticals.
- Monthly visits10.7K
▲ 51.6% vs previous month
- Unique visitors3.4K
per month
- Global rank#2,716,683
among all websites
- Category rank#3,677
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit2.0
- Average visit44 sec
- DevicesDesktop 53% · Mobile 47%
Websites whose visitors overlap most with OM Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| viforpharma.com | 100% | – | – | View details | |
| swissbiotech.org | 92% | 63.9K | #658,452 | View details | |
intercomservice.com | intercomservice.com | 26% | – | – | – |
salon-auto.ch | salon-auto.ch | 26% | – | – | – |
ktnm.com | ktnm.com | 26% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 20 similar websites and full traffic analytics for OM Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 20 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Om Pharma
Complete news archive for OM Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to OM Pharma
10 companies that operate in the same segment as OM Pharma (Genitourinary Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | – | – | |
Provider of surgical devices for vertical hernia repair and abdominal wall reconstruction | 2012 | Malvern, Pennsylvania, United States | USD 104.6 M | USD 80.28 M | 209 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Miniaturized injectable neuromodulation devices are developed for chronic diseases. | 2014 | Santa Clara, California, United States | USD 123.59 M | – | – | |
Developer of a therapeutic solution to treat prostate, kidney, and bladder cancer | 2018 | Maple Grove, Minnesota, United States | USD 157 M | – | 29 | |
A device is developed to treat urinary obstruction from BPH. | 2014 | Palo Alto, California, United States | USD 48 M | – | 25 | |
Minimally invasive devices in urology | 2004 | Mountain View, California, United States | USD 137.96 M | – | 119 | |
Diagnostic devices for lower urinary tract diseases are developed. | 2021 | Aliso Viejo, California, United States | USD 94.99 M | – | 23 | |
Medical device for benign prostatic hyperplasia treatment is developed. | 2021 | Milwaukee, Wisconsin, United States | USD 54.16 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about OM Pharma
OM Pharma was founded in 1937.
OM Pharma is headquartered in Meyrin, Switzerland. It is registered at Meyrin, Geneva, Switzerland.
Founded in 1937 and based in Meyrin, Switzerland, therapeutics are developed by the company for respiratory, urology, central nervous system, and vascular diseases. Drugs based on oral, lyophilized bacterial extracts form the core of its operations within the pharmaceutical sector. Focus is placed on treatments for multiple conditions, with activities centered in Europe.
OM Pharma's top competitors include Vaxcyte, Serum Institute of India and Biological E.
OM Pharma has 1 investor. Key investors include Optimus Holding.
Yes. OM Pharma was acquired by Optimus Holding in September 2020.